This bill (Senate Bill 5781, S-1552.1, 69th Legislature, 2025 Regular Session) creates a new chapter in Title 70 RCW. It requires the Washington State Department of Health, other executive branch agencies (including the governor’s office), and local health departments to promote, distribute, or endorse FDA-regulated products only in ways that comply with the conditions of FDA authorization or approval as stated in FDA labeling. For statements about a general class of FDA-regulated products the bill requires either universally true assertions under current FDA rules or clear qualifications about exceptions; it also bars use of funding or inducements that would lead to information inconsistent with FDA labeling, requires notices when directing people to sources not covered by the section, and permits public criticism of FDA decisions. Preexisting informational materials that do not comply must be withdrawn within 30 days of the section’s effective date (the effective date is not specified in the provided text). The bill creates administrative and procedural requirements: agencies must adopt internal review processes to ensure compliance, must immediately stop dissemination and issue correction notices when a violation is found, and must submit annual reports to the state auditor detailing compliance efforts, violations, and corrective actions. The state auditor is directed to accept and investigate complaints about violations, to protect complainants from retaliation, and to treat evidence of retaliation as a separate violation to investigate. The change is a new statutory compliance regime and administrative enforcement structure rather than a criminal law. It establishes procedural changes, reporting duties, administrative oversight by the state auditor, and possible employment disciplinary consequences: violations by executive branch or local health department employees may result in discipline up to and including termination. The act includes definitions for key terms (for example, “department,” “executive branch,” “FDA labeling,” and “FDA regulated product”) and contains a severability clause. Important details are missing from the provided text: no specific effective date or precise new RCW section numbers are given; the bill does not set out detailed procedures for how disciplinary actions will be implemented beyond allowing termination; and terms such as “promote,” “distribute,” “endorse,” and “inducements” could be open to interpretation without further statutory or regulatory clarification. The bill’s findings reference particular assertions and reports but supporting documents are not included in the excerpt.

If enacted, Washington’s Department of Health, the governor’s office, state agencies, and local health departments would have to make sure any promotion, distribution, or endorsement of FDA-regulated products matches the exact conditions in FDA labeling, pull any existing materials that don’t comply within 30 days of the law taking effect (the actual effective date isn’t provided), and put internal review systems in place. That will most directly affect agency communications staff and contractors who produce public health outreach: they will likely need to revise or remove materials, add review and approval steps, change contract language with vendors, and provide notices when pointing providers or the public to outside information that might not follow FDA labeling. Practically, agencies should expect added administrative costs and staff time for compliance reviews, training, and faster-turnaround edits or withdrawals of materials, and there is a real risk for individual employees because violations can lead to discipline up to termination. The state auditor will receive annual compliance reports, accept and investigate complaints, and look into retaliation claims, increasing oversight and potential operational consequences for agencies. Important details remain unclear in the text provided, including the law’s effective date and the specific processes for disciplining employees.